Wegovi, the maker of the popular weight-loss drug. Said Wednesday it is ramping up production of the drug. Which is in short supply at pharmacies across the United States.
Novo Nordisk said on Dec. 28 that all doses of the drug would be available again after . The supply problem, but added that it could take time for the drug to reach . Pharmacies from distribution centers.
There continues to be “pent up demand” for Wegovi, but Novo Nordisk expects that to become . less of a problem as more supplies of the drug become available in the coming months, Jorgensen said.
“We’re encouraged by . The trendline we see, but there will be a normalization of it,” he said.
Wegovi, or semaglutide, is part of a class of drugs called GLP-1 agonists. They mimic a hormone that helps reduce food intake and curb hunger. In clinical trials, Wegovy has been shown to reduce body by about 15%.
The drug is expensive, costing about $1,300 per month, and insurance companies often don’t cover it.
Wegovi shortages have forced some . People in the United States to stop taking it, causing them to regain some — or all — of their weight.
Doug Langa, head of Novo Nordisk’s . North American operations, noted on the call the difficulty patients . Have had in finding the drug, but added that the company is now . looking forward” to the drug becoming more available.